Pfizer’s PCV20 offers single-shot protection against 20 pneumococcal serotypes, safeguarding adults from serious respiratory ...

A next-generation pneumococcal conjugate vaccine, PCV20, a single-dose protection is now available in India marking a new ...

Alongside its results, the company announced a significant product launch. On August 11, Pfizer rolled out its ...

Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 ...

Pfizer has introduced its 20-valent pneumococcal conjugate vaccine, PCV20, in India to provide protection against 20 serotypes of pneumococcal disease. The single-shot vaccine is aimed at adults, ...

This follows the recent announcement that the Health Ministry has approved the 20-valent pneumococcal conjugate vaccine ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

PCV20 includes all 13 serotypes in PCV13, along with seven additional serotypes “that are responsible for a substantial amount of the residual disease burden,” he added.

Pfizer introduces its next-gen 20-valent pneumococcal conjugate vaccine (PCV20) in India for adult immunization against 20 ...

The study compared VAX-31 to PCV20 in 1,015 healthy adults aged 50 and older. The company has selected VAX-31 to advance to an adult Phase 3 program.

In a statement, Pfizer stated PCV20 offers a broader pneumococcal conjugate vaccine option in Malaysia, providing coverage against 20 serotypes of Streptococcus pneumoniae, the bacteria responsible ...